IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. It has a strategic research and license agreement with AbCellera to discover and develop IgM antibodies; and license agreement with AvantGen Inc. for various antibodies against the SARS-CoV-2 virus. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
IPO Year: 2019
Exchange: NASDAQ
Website: igmbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $21.00 → $2.00 | Outperform → Market Perform | BMO Capital Markets |
| 1/10/2025 | $12.00 → $2.00 | Equal-Weight → Underweight | Morgan Stanley |
| 1/10/2025 | $27.00 → $2.50 | Buy → Hold | Stifel |
| 1/10/2025 | $20.00 → $1.50 | Outperform → Sector Perform | RBC Capital Mkts |
| 1/10/2025 | Buy → Neutral | Guggenheim | |
| 12/6/2024 | $21.00 | Outperform | BMO Capital Markets |
| 10/1/2024 | $12.00 → $9.00 | Neutral → Underweight | JP Morgan |
| 10/1/2024 | $24.00 → $12.00 | Buy → Hold | Truist |
| 2/9/2024 | $9.00 → $21.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 12/15/2023 | $8.00 | Buy → Neutral | BofA Securities |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
Fastest customizable press release news feed in the world
MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ("Concentra"), whereby Concentra will acquire IGM Biosciences for $1.247 in cash per share of IGM Biosciences common stock ("Common Stock"), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 100% of the closing net cash of IGM Biosciences in excess of $82.0 million; and (ii) 80% of any net proceeds received within one year fol
– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory diseases, today announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases. "Interim data
– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended September 30, 2024 and provided an update on recent developments. "The third quarter was transformative for IGM, punct
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences: Guggenheim Healthcare Innovation Conference on Monday, November 11 at 11:30 a.m. EST in BostonStifel Healthcare Conference on Tuesday, November 19 at 12:40 p.m. EST in New YorkJefferies London Healthcare Conference on Thursday, November 21 at 8:00 a.m. GMT/ 3:00 a.m. EST in London A live webcast of the events will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at http
– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth Harler, M.D., appointed as Chief Executive Officer and to Board of Directors – – Cash runway extended into 2027 – – Company to hold conference call and webcast today at 4:30 p.m. EDT – MOUNTAIN VIEW, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in the development
MOUNTAIN VIEW, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, and Mary Beth Harler, M.D., Head, Research & Autoimmunity, will participate in a fireside chat at the Stifel 2024 Virtual Immunology and Inflammation Summit on Tuesday, September 17, 2024, at 9:00 a.m. EDT. A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be a
– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – – Second dose cohort cleared in imvotamab rheumatoid arthritis clinical trial – – First dose cohort cleared in imvotamab systemic lupus erythematosus clinical trial – MOUNTAIN VIEW, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended June 30, 2024 and provided an update on recent developments. "We continue to make significant progress in the clinical
MOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 5, 2024, at 2:30 p.m. EDT in New York. A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. Ab
- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments. "We are pleased to have exceeded our enrollment target of 110 patients in our randomized study of 3 mg/kg of aplitabart plus FOLFIRI and bevacizumab in second line colorectal cancer," said Fred Schwa
MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference on Tuesday, May 14, 2024, at 2:35 p.m. EDT. A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About IGM Biosciences, Inc.IGM Bio
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
BMO Capital Markets downgraded IGM Biosciences from Outperform to Market Perform and set a new price target of $2.00 from $21.00 previously
Morgan Stanley downgraded IGM Biosciences from Equal-Weight to Underweight and set a new price target of $2.00 from $12.00 previously
Stifel downgraded IGM Biosciences from Buy to Hold and set a new price target of $2.50 from $27.00 previously
RBC Capital Mkts downgraded IGM Biosciences from Outperform to Sector Perform and set a new price target of $1.50 from $20.00 previously
Guggenheim downgraded IGM Biosciences from Buy to Neutral
BMO Capital Markets initiated coverage of IGM Biosciences with a rating of Outperform and set a new price target of $21.00
JP Morgan downgraded IGM Biosciences from Neutral to Underweight and set a new price target of $9.00 from $12.00 previously
Truist downgraded IGM Biosciences from Buy to Hold and set a new price target of $12.00 from $24.00 previously
RBC Capital Mkts upgraded IGM Biosciences from Sector Perform to Outperform and set a new price target of $21.00 from $9.00 previously
BofA Securities downgraded IGM Biosciences from Buy to Neutral and set a new price target of $8.00
15-12G - IGM Biosciences, Inc. (0001496323) (Filer)
SCHEDULE 13D/A - IGM Biosciences, Inc. (0001496323) (Subject)
SCHEDULE 13D/A - IGM Biosciences, Inc. (0001496323) (Subject)
EFFECT - IGM Biosciences, Inc. (0001496323) (Filer)
EFFECT - IGM Biosciences, Inc. (0001496323) (Filer)
EFFECT - IGM Biosciences, Inc. (0001496323) (Filer)
EFFECT - IGM Biosciences, Inc. (0001496323) (Filer)
EFFECT - IGM Biosciences, Inc. (0001496323) (Filer)
S-8 POS - IGM Biosciences, Inc. (0001496323) (Filer)
S-8 POS - IGM Biosciences, Inc. (0001496323) (Filer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
Live Leadership Updates
STOCKHOLM, Oct. 25, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors has appointed Jens Lindberg as CEO of the company. Jens Lindberg has extensive experience from the pharmaceutical industry and the field of Oncology. He joins from Sedana Medical where he has been VP Commercial and acting CEO. Jens Lindberg started his career in the pharmaceutical industry in 1995 as a sales representative for Astra, later AstraZeneca. During a 25-year span at AstraZeneca, Jens held numerous roles in Commercial & Investor Relations, spanning local & global responsibilities as well as development of phase 2/3 programs to maximise the commercial value for o
– John Shiver, Ph.D., and Tong-Ming Fu, M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious Diseases – – Mary Beth Harler, M.D., Appointed as President of IGM Autoimmunity and Inflammation – MOUNTAIN VIEW, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the formation of two business units: IGM Infectious Diseases and IGM Autoimmunity and Inflammation. These new business units will utilize and build upon IGM's platform technology to create and develop novel IgM and IgA antibodies to ad
STOCKHOLM, July 1, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Malene Jensen as Vice President Clinical Development. She will assume her role as VP Clinical Development after the summer, at the latest October 1, 2021. Malene Jensen will also join the company's executive team. Malene Jensen has held various leadership positions within Clinical Development in the pharmaceutical industry for the past 15 years, including at AstraZeneca, Affibody and most recently as Director Global Clinical Development at Sedana Medical. She holds a PhD in Clinical Neuroscience from Karolinska Institutet in Stockholm. "We are pleased to welcome Malene and her vast cl
STOCKHOLM, April 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that its Board of Directors appoints Magnus Christensen, the company's CFO, as interim CEO of Medivir. Magnus has been CFO of the company since 2019 and will take up his new role in connection with Medivir's Annual General Meeting on May 5, 2021. Magnus will in parallel retain his role as CFO. As previously communicated, Yilmaz Mahshid will leave his position as CEO at the Annual General Meeting (AGM) 2021. Medivir's nomination committe proposes that Yilmaz Mahshid is elected new board member at the AGM. The Board has initiated the recruitment process for a new CEO. - Magnus Christensen has been a
MOUNTAIN VIEW, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of George A. Gauthier to the newly created position of Chief Commercial Officer. Mr. Gauthier joins IGM with twenty years of experience in global commercial strategy, marketing, sales and product development. Most recently, Mr. Gauthier was Vice President of Global Product Strategy for Breast and Gynecological Cancers at Genentech, where he led a global team in the creation and execution of commercial and product development strategies. "We are delighted to have Ge
Live finance-specific insights
– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended September 30, 2024 and provided an update on recent developments. "The third quarter was transformative for IGM, punct
– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth Harler, M.D., appointed as Chief Executive Officer and to Board of Directors – – Cash runway extended into 2027 – – Company to hold conference call and webcast today at 4:30 p.m. EDT – MOUNTAIN VIEW, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in the development
– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – – Second dose cohort cleared in imvotamab rheumatoid arthritis clinical trial – – First dose cohort cleared in imvotamab systemic lupus erythematosus clinical trial – MOUNTAIN VIEW, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended June 30, 2024 and provided an update on recent developments. "We continue to make significant progress in the clinical
- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments. "We are pleased to have exceeded our enrollment target of 110 patients in our randomized study of 3 mg/kg of aplitabart plus FOLFIRI and bevacizumab in second line colorectal cancer," said Fred Schwa
MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments. "We made significant progress during 2023 in the clinical development of our two lead product candidates in therapeutic areas that we believe have the greatest potential to produce significant near-term value," said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. "Enrollment in our randomized clinical trial of aplitabart plus FOLFIRI and bevacizumab in
– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended September 30, 2023. "During the third quarter, we continued to execute across our clinical development pipeline," said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. "We have significantly expanded the number of active sites for our aplitabart randomized study, including multiple international s
– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer patients – – Progression-free survival of 5.6 months in median third-line colorectal cancer patients without bevacizumab – – Promising safety profile in combination with FOLFIRI and bevacizumab – – Randomized combination trial in second-line colorectal cancer patients initiated in Q1 2023 – MOUNTAIN VIEW, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced an update on its clinical development program for IGM-
– Event to be webcast live on Friday, June 2, 2023 at 7:00 p.m. ET – MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that it will host a conference call and live webcast to provide an update on its clinical development program for IGM-8444, a novel multivalent DR5 agonist, on Friday, June 2, 2023 at 7:00 p.m. ET. The Company will be providing a clinical data update on 3 mg/kg IGM-8444 + FOLFIRI (± bevacizumab) in median third line metastatic colorectal cancer patients from a non-randomized clinical trial cohort. The event will feature
HUDDINGE, Sweden, May 16, 2023 /PRNewswire/ -- In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) ("Medivir") on 4 May 2023 ("LTIP 2023"), it is today announced that the board of directors of Medivir has resolved on (i) a share issue of 970,500 shares of series C, (ii) repurchase of the 970,500 shares of series C, (iii) reclassification of 105,750 shares of series C into ordinary shares and (iv) partial execution of the annual general meeting's resolution on transfer of own ordinary shares by transferring 105,750 own ordinary shares to participants in LTIP 2023. Aktieinvest FK AB will subscribe for all 970,500 shares of series C at a subscription pri
– Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway – – Plans to present additional non-randomized clinical data for 3 mg/kg of IGM-8444 plus FOLFIRI, with and without bevacizumab, in the middle of 2023 – – Plans to begin clinical testing of imvotamab in severe systemic lupus erythematosus and severe rheumatoid arthritis – MOUNTAIN VIEW, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the first quarter ended March 31, 2023 and provided an update on
This live feed shows all institutional transactions in real time.
SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13D/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13G - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13D/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13D/A - IGM Biosciences, Inc. (0001496323) (Subject)